Patents by Inventor Carlos Duarte Cano

Carlos Duarte Cano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080280354
    Abstract: The invention relates to HIV chimeric gene formed by the union of fragments of different genes of said virus, wherein said fragments contains epitopes for cytotoxic T cells (CTL) or HIV-1 auxiliary T cells, which are presented by a wide range of antigens of type Major Histocompatibility Complex (HLA-I). Recombinant poxviruses are obtained from said genes, which are useful for prophylactic and therapeutic vaccination against HIV/AIDS infections, are capable of generating a protective immune cell response in vaccinated laboratory animals and are recognized by the CTL lymphocytes of HIV/AIDS patients.
    Type: Application
    Filed: July 14, 2006
    Publication date: November 13, 2008
    Inventors: Enrique Iglesias Perez, Dania M. Vazquez Blomquist, Carlos A. Duarte Cano
  • Patent number: 7318927
    Abstract: The invention relates to HIV chimeric gene formed by the union of fragments of different genes of said virus, wherein said fragments contains epitopes for cytotoxic T cells (CTL) or HIV-1 auxiliary T cells, which are presented by a wide range of antigens of type Major Histocompatibility Complex (HLA-I). Recombinant poxviruses are obtained from said genes, which are useful for prophylactic and therapeutic vaccination against HIV/AIDS infections, are capable of generating a protective immune cell response in vaccinated laboratory animals and are recognized by the CTL lymphocytes of HIV/AIDS patients.
    Type: Grant
    Filed: February 22, 2002
    Date of Patent: January 15, 2008
    Assignee: Centro de Ingenieria Genetica y Biotecnologia
    Inventors: Enrique Iglesias Perez, Dania M. Vazquez Blomquist, Carlos A. Duarte Cano
  • Publication number: 20070275012
    Abstract: The present invention is related with the field of therapeutic vaccines against pathogens causing chronic diseases. It comprises the use in therapy of formulations containing the Hepatitis B surface antigen (HBsAg) as the main compound. The HBsAg is produced as a recombinant product in Picchia pastoris. The formulations of the present invention also comprise the combination of the Hepatitis B surface antigen and other coadministered antigens. The resulting formulations are able to generate potent lymphoprolipherative and cytotoxic responses apart from a remarkable response of specific antibodies, which make them very effective in the treatment of such diseases.
    Type: Application
    Filed: October 20, 2004
    Publication date: November 29, 2007
    Inventors: Julio Aguilar Rubido, Enrique Iglesias Perez, Yadira Lobaina Mato, Daymir Garcia Gonzalez, Verena Muzio Gonzalez, Gerardo Guillen Nieto, Nelson Acosta Rivero, Raimundo Ubieta Gomez, Julio Alvarez Obregon, Santiago Duenas Carrera, Carlos Duarte Cano, Peter Vanlandshoot, Luis Herrera Martinez
  • Publication number: 20040073008
    Abstract: The invention relates to HIV chimeric gene formed by the union of fragments of different genes of said virus, wherein said fragments contains epitopes for cytotoxic T cells (CTL) or HIV-1 auxiliary T cells, which are presented by a wide range of antigens of type Major Histocompatibility Complex (HLA-I). Recombinant poxviruses are obtained from said genes, which are useful for prophylactic and therapeutic vaccination against HIV/AIDS infections, are capable of generating a protective immune cell response in vaccinated laboratory animals and are recognized by the CTL lymphocytes of HIV/AIDS patients.
    Type: Application
    Filed: August 27, 2003
    Publication date: April 15, 2004
    Inventors: Enrique Iglesias Perez, Dania M Vazquez Blomquist, Carlos A Duarte Cano